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Abstract: Besides orthotopic liver transplantation (OLT) there is no long-term and eff ective replacement therapy for severe liver failure. 
Artiﬁ cial extracorporeal liver supply devices are able to reduce blood toxin levels, but do not replace any synthetic function of the liver. Molecular 
adsorbent recirculating system (MARS) is one of the methods that can be used to treat fulminant acute liver failure (ALF) or acute on chronic 
liver failure (AoCLF). The primary non-function (PNF) of the newly transplanted liver manifests in the clinical settings exactly like acute liver 
failure. MARS treatment can reduce the severity of complications by eliminating blood toxins, so that it can help hepatic encephalopathy (HE), 
hepatorenal syndrome (HRS), and the high rate mortality of cerebral herniation. This might serve as a bridging therapy before orthotopic liver 
retransplantation (reOLT). Three patients after a ﬁ rst liver transplantation became candidate for urgent MARS treatment as a bridging solution 
prior to reOLT in our center. Authors report these three cases, focusing on indications, MARS sessions, clinical courses, and ﬁ nal outcomes.
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Introduction
Severe liver failure is a life threatening disorder with 
high mortality rate. Multiple causes with various pa-
thologies can lead to irreversible liver insuffi  ciency. De-
spite intensive care treatment patient survival rate is at 
the low level of 20–60% without orthotopic liver trans-
plantation (OLT), which is the only deﬁ nite solution 
for acute liver failure (ALF). The availability of OLT 
is limited due to the well-known donor organ short-
age that enforces clinicians to adjust alternative medica-
tion to gain time until a suitable donor organ becomes 
available. Despite adequate intensive therapy ALF and 
acute on chronic liver failure (AoCLF) can lead to mul-
tiorgan failure (MOF). Besides usual intensive therapy, 
extracorporeal assist devices can be eff ective help as a 
complement medical treatment option.
Liver failure causes hepatorenal syndrome (HRS) 
with acute renal failure, hepatopulmonary syndrome 
(HPS) with respiratory failure, severe disseminated co-
agulopathy, acute encephalopathy, hemodynamic ab-
erration, and severe sepsis [1]. Considering the com-
mon pathway of liver failure, it can be divided into the 
following categories: acute liver failure (ALF), acute 
on chronic liver failure (AoCLF), and end stage liver 
disease. The etiology of ALF can be primary, such as 
toxin- or drug-induced insults, fulminant hepatotropic 
viral infections, and metabolic disorders (like Wilson’s 
disease), and also can be secondary ALF that can arise 
from cardiovascular reasons such as cardiogenic shock 
or severe sepsis. AoCLF occurs when a sudden event 
(gastrointestinal bleeding, alcohol abuse, or infection) 
leads to the acute deterioration of liver function in pa-
tients with pre-existing compensated chronic liver dis-
ease or cirrhosis [2]. 
Since 1970s, plasmapheresis was clinically endeav-
ored for treatment of fulminant liver insuffi  ciency with 
moderate results, reaching 40% of survival rate com-
pared to 20–25% with supportive therapy [3]. Bioar-
tiﬁ cial methods are capable to replace both synthetic 
and detoxicating function of the liver, but are still in 
experimental phase and still awaiting widespread human 
clinical application. Artiﬁ cial liver supply methods are 
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already available since 1999, as costly but highly eff ective 
choices for temporary treatment of liver failure. These 
devices are intended to remove both protein-bound and 
water-soluble toxins, although provide no supplement 
the synthetic function of the liver. Three systems spread 
in Europe, each using albumin dialysis. Single pass albu-
min dialysis (SPAD) uses a continuous veno-venosous 
hemodiaﬁ ltration (CVVH) that contains a standard di-
alysis solution with additional 4.4% albumin. Molecular 
adsorbent recirculating system (MARS) uses two dialyz-
ing circuits, an albumin (20%), and a renal circuit. The 
albumin dialysate is subsequently cleaned by a charcoal 
and an ion exchanging column. By eliminating bilirubin, 
ammonia, lactate, aromatic amino acids, and free fatty 
acids from plasma, detoxication can prevent the patient 
from the fatal complication of hepatic encephalopathy 
(HE) and reduce the high mortality rate of brain edema 
and cerebral herniation. Fractionated plasma separation 
and adsorption (FPSA) system is diff erent: the patient’s 
albumin is separated across a membrane and then dia-
lyzed through adsorptive columns. This method is used 
in Prometheus device that combines FPSA method with 
high-ﬂ ux hemodialysis [3, 4]. Several publications have 
arisen in the past decade proving the clinical beneﬁ ts 
of each system, but no such a complete and long-term 
treatment is assured by any of these methods as it is by 
hemodialysis for end stage renal failure patients.
As formerly mentioned OLT is the best solution for 
liver failure, but what is to be done when a post-trans-
plant patient is suff ering from acute or acute on chronic 
liver failure? A special category of parenchymal causes for 
ALF could be the insuffi  ciency of a newly transplanted 
liver in form of a primary non-function (PNF). PNF oc-
curs in 3–6% after OLT and is a feared complication that 
can evolve due to organ preservation injury, prolonged 
cold ischemic time (CIT) or warm ischemic time (WIT), 
fatty transplanted liver, organ retrieved from extended 
criteria donor (age, hypernatremia, grafts from donation 
after cardiac death), and OLT for a very high MELD 
score recipient. PNF shows the symptoms and signs of 
ALF with elevated liver transaminase level, jaundice, 
encephalopathy, coagulopathy, and, in severe cases, re-
nal and respiratory complications [5]. After a success-
ful OLT, long-term survival is greatly inﬂ uenced by the 
recurrence of original liver disease. Alcoholism, viral in-
fection, bilio-congestive, and autoimmune disorders can 
reoccur and lead to the slow deterioration of transplant-
ed liver [6]. Fulminant relapses of these chronic diseases 
can also appear as AoCLF in transplanted patients as well 
as in non-transplant patients.
Case Reports
Five hundred and twelve liver transplantations have been 
performed between 1995 and 2012 in our department. 
Among these transplantations, 34 were orthotopic liver 
retransplantation (reOLT), 33 secondary, and 1 tertiary. 
Among the 34 reOLT cases, the original indication for 
transplantation was mainly hepatitis C virus (HCV), au-
toimmune hepatitis, ALF [7], cryptogen cirrhosis, pri-
mary sclerosing cholangitis (PSC), and other cholestatic 
disorders. Seventeen of the reOLTs were done in the 
early postoperative course (within 3 months) and 17 
in the late postoperative period. More than half (60%) 
of the early retransplantations were needed because of 
Table I Data on the presented cases show that subsequent MARS treatments could not stop the progression of liver failure in case 2 and 
case 3. An increase in MELD score was detected. Regression of MELD score in case 1 could be explained by the short period of time 
between operations
Case 1 Case 2 Case 3
Age (by the time of reOLT) 54 65 30
Gender Male Female Female
Primary indication HCV + alcohol PBC PSC
MELD before OLT 12 12 n/a
CIT for OLT 10 h 58 min 6 h 2 min 7 h 44 min
Length of operation 10 h 25 min 5 h 10 min 5 h 25 min
OLT blood transfusion 3200 mL 800 ml 1000 mL
OLT complication VC anastomosis 2× resuturing VC anastomosis resuturing, fatty donor liver None
Inter OLT period 4 days 11 days 7 years
Secondary indication PNF – ALF PNF – ALF PSC – AoCLF
MELD before MARS session 32.50 27.20 29.50
MELD before reOLT 31.10 32.60 32.60
No. of MARS treatments 2 5 4
Renal replacement therapy Yes No Yes
Survival >14 months >21 months 26 months
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hepatic artery thrombosis (HAT) [8] and 20–20% for 
PNF and venous outﬂ ow disturbance. Only three of 
these patients had received extracorporeal liver replace-
ment therapy before reOLT. MARS device was used in 
a various sequence depending on the clinical status of 
patients, and also, the duration for application usage also 
varied. Highlighted data and information are present-
ed in Table  I, and the timing and length of individual 
MARS treatments are shown in Table II.
Case 1
The ﬁ rst presented patient is a 54-year-old male, who 
had alcohol-induced chronic liver failure turned to cir-
rhosis, but also had formerly received interferon therapy 
as HCV treatment with no response. His clinical status 
proceeded, while parenchymal and vascular decompen-
sation evolved. Preoperative examinations had proved 
grade II esophageal varices, type 2 diabetes mellitus, 
and a recurring hospitalization due to severe hepatic 
encephalopathy. OLT was performed using cross-clamp 
method. This is to be mentioned that the upper anas-
tomosis of the vena cava (VC) needed to be resutured 
twice, with the opening of the pericardium, which led 
to an extended WIT. During transplantation, excessive 
amount of blood transfusion was necessary. In the im-
mediate postoperative course, further blood, plasma, 
and thrombocyte transfusions were needed. After the 
exclusion of other possible causes, and according to rel-
evant laboratory results, PNF was diagnosed. Urgent 
MARS treatments were carried out in two sessions, ﬁ rst 
3 days after OLT (8-h session) and second on the day of 
retransplantation, right before the procedure (5-h treat-
ment). ReOLT was performed on the fourth day after 
primary transplantation requiring further blood transfu-
sion and thrombocyte supplement. During reOLT, the 
abdominal wall could only be reconstructed with the 
implantation of dual layer mesh to avoid compression 
on the liver graft. As the edema of the liver decreased, 
the mesh was explanted, after a few days. Extended post-
operative course included temporary CVVH, hemodi-
aﬁ ltration, and hemodialysis by reason of renal insuffi  -
ciency, but ﬁ nally, kidney function became settled. Both 
synthetic and detoxicating function of the liver improved 
rapidly after reOLT. The patient was treated for lobar 
pneumonia and later dismissed in a good status. He does 
well so far.
Case 2
A 65-year-old woman suff ered from primary biliary cir-
rhosis (PBC) and had been referred to our department. 
Several endoscopic sclerotherapies were carried out pre-
viously, and a splenorenal shunt operation was executed 
because of portal hypertension and repeated variceal 
bleeding. The patient underwent OLT in 2011, when 
a 22-year-old brain-dead donor was off ered with a mod-
erate fatty donor liver. OLT was performed with cross-
clamp technique. The preexisting splenorenal shunt was 
not ligated during the operation. This decision later 
turned out to be a mistake. During the suturing of the 
upper VC anastomosis, some technical diffi  culties had 
arisen for what the resuturing became necessary with a 
prolonged WIT. During the next days, initial poor func-
tion (IPF) of the transplanted liver was detected, with 
permanently increased serum bilirubin and INR, and a 
concomitant diminished portal ﬂ ow. This was due to the 
formerly processed and still working splenorenal shunt. 
Radiological interventions were used to reduce the cir-
culation of the shunt and strengthen portal ﬂ ow, with a 
moderate success. MARS treatment was ﬁ ve times sub-
sequently performed to reduce toxic substance levels and 
consequent encephalopathy. By this time, the outﬂ ow 
from the liver graft via the re-sutured VC anastomosis 
became normal.
After several days of deteriorating state in spite of all 
eff orts, urgent need for retransplantation was declared 
with the indication of PNF and compromised portal in-
ﬂ ow. By the usage of MARS, the patient had survived 
until the 11th postoperative day when a suitable donor 
was reported, and the reOLT was performed, with AB0 
identical and CMV +/+ full sized graft, and cross-clamp 
technique. The postoperative ultrasonography showed 
an extended subcapsular hematoma in the right lobe, 
which needed no surgical intervention and dissolved af-
ter time. The function of the transplanted liver improved 
stepwise. Eighteen days after reOLT, suddenly the symp-
toms of peritonitis appeared; thus, a further urgent reop-
eration was done. During the operation, the perforation 
Table II Timing and length of individual MARS treatments for 
each patient reﬂ ect the fulmination of liver failure. In case 
1 and case 2, MARS was on subsequent days and less fre-
quent in case 3. In case 1 and case 3, a shorter treatment 





Case 1 MARS I T-1 8
MARS II T 5
Case 2 MARS I T-7 9
MARS II T-6 8
MARS III T-5 8
MARS IV T-3 7
MARS V T-1 8
Case 3 MARS I T-13 8
MARS II T-11 8
MARS III T-6 8
MARS IV T 5
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of the transverse colon was diagnosed and a biluminar 
transversostomy was created. The patient was then treat-
ed extensively in our intensive care unit, due to critical 
illness neuropathy, that occurred with the paresis of the 
lower limbs, besides deep vein thrombosis and Herpes 
zoster infection. Finally, the patient was dismissed with 
minor remnant complaints. Long-term follow-up re-
corded full recovery.
Case 3
Young female patient suff ering from primary sclerosing 
cholangitis (PSC) had received a full sized AB0 compat-
ible cadaver liver graft OLT at the age of 23. Three years 
later, the possible relapse of PSC and the obstruction of 
common bile duct were justiﬁ ed; thus, a choledocho-
jejunostomy was performed. Since then, a more frequent 
hospitalization was necessary due to recurrent ascending 
cholangitis. Seven years after the primary OLT, the pa-
tient’s status has gradually deteriorated. After admission 
for symptoms of cholangitis, a rapidly worsening hepat-
ic function was observed, and despite proper intensive 
care, ALF with encephalopathy had evolved. ReOLT was 
decided due to the possible relapse of PSC, and the van-
ished bile ducts syndrome, with jaundice, and the signs 
of AoCLF. Four sessions of consecutive MARS treatment 
were necessary until a proper donor has been reported, 
and the urgent reOLT was performed. The operation 
was carried out with the cross-clamp technique, and the 
bile ducts were reconstructed via hepatico-jejunostomy 
using the formerly created jejunum limb. In the early 
postoperative period, a reoperation was done to evacuate 
an intraabdominal hematoma. Further, a histologically 
veriﬁ ed, mild (1/9 grade) acute rejection was treated 
with steroid bolus (3 times 1000 mg Solu Medrol), and 
due to kidney impairment, hemodialysis was necessary 
twice. The patient left our departments with no com-
plaints.
One year after reOLT, the formerly known, but re-
mittent ulcerative colitis relapsed. The adequate drug 
therapy was administered. Two years after reOLT, the 
patient was admitted to our hospital for manifest ascend-
ing cholangitis and bile duct obstruction had developed. 
The conclusion was the diagnosis of repeated relapse of 
PSC. The percutaneous transhepatic drainage of biliary 
system was done, but besides adequate therapy (hemo-
dialysis, plasma pheresis, and steroid treatment), a pro-
gressive AoCLF, septic status, and consecutive HRS and 
HE evolved. Hemodialysis, plasmapheresis, and steroid 
treatment were induced. Due to severe gastrointestinal 
bleeding from the colon, an urgent subtotal colectomy 
was done, and also an almost immediate reoperation af-
terwards due to bleeding complication. The histology 
has proved the severe (Mayo score: 3) relapse of ulcer-
ative colitis of the entire colon. In spite of the further in-
tensive care, the patient’s status deteriorated, and MOF 
evolved. Contraindication for tertiary liver transplan-
tation was declared with the reason of septicemia, ex-
pected prognosis, and surgical technical considerations 
together. The patient shortly passed away.
Laboratory tests were made before and after each 
MARS treatment, in case of all patients and cases. Data 
are summarized in Table III. Serum levels, of renal func-
tion parameters, liver enzymes, bilirubin, and lactate de-
hydrogenase (LDH), and lactate levels all decreased after 
Table III Serum parameters in eff ect of MARS treatments. Albumin and INR results are also inﬂ uenced by exo-
genous supplement. Decrease in the level of cholinesterase, and the slight increase of ammonia level 
shows that MARS therapy could not entirely keep up with the progression of liver failure
Parameter Unit Before MARS After MARS Percent change p Value
Carbamide mmol/L 20.5 ± 12.0 13.7 ± 6.7 −0.3318 0.0488
Creatinine μmol/L 213.6 ± 85.7 151.8 ± 51.7 −0.2891 0.0155
Bilirubin, total μmol/L 411.4 ± 250.0 325.6 ± 156.0 −0.2085 0.0126
Bilirubin, conj. μmol/L 318.8 ± 237.0 224.0 ± 147.5 −0.2972 0.0077
ALP U/L 272.7 ± 115.8 234.6 ± 89.5 −0.1397 0.0607
SGOT U/L 535.5 ± 746.7 375.9 ± 379.7 −0.2981 0.0856
SGPT U/L 420.2 ± 450.9 368.4 ± 353.7 −0.1232 0.0152
GGT U/L 108.9 ± 65.0 92.9 ± 54.5 −0.147 0.0210
LDH U/L 702.0 ± 382.3 462.9 ± 272.4 −0.3406 0.1122
Lactate mmol/L 7.2 ± 1.5 4.7 ± 1.8 −0.3431 N/A
Cholinesterase U/L 5897.9 ± 1514.2 5198.5 ± 1348.2 −0.1186 0.0876
Ammonia μmol/L 73.6 ± 56.4 75.0 ± 49.8  0.019 0.2995
Albumin g/L 37.3 ± 5.67 43.6 ± 10.33  0.1693 0.0247
INR  1.8 ± 0.6 1.9 ± 0.5  0.0875 0.2443
MELD  32.1 ± 4.5 28.4 ± 4.2 −0.1144 0.028
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MARS treatment. Decrease was signiﬁ cant (p < 0.05) 
for carbamide, creatinine, total and conjugated biliru-
bin, SGPT and GGT compared to the initial blood level. 
On the other hand, it is to be noticed, that serum am-
monia levels did not show decrease, but a slight, non-
signiﬁ cant (from 73.6 ± 56.4 μmol/L to 75.0 ± 49.8 
μmol/L, p = 0.2995) increase was observed, showing 
that MARS treatment could not keep up with the pro-
gression of ALF. INR showed a negligible (8.75%, p = 
0.2443) increase after MARS. MARS therapy did not 
substitute the synthetic function of the liver, and the 
decrease of cholinesterase level (from 5897.9 ± 1514.2 
U/L to 5198.5 ± 1348.2 U/L, p = 0.0876) reﬂ ects a 
perishing change in liver’s synthetic function. The con-
siderable (p = 0.0247) elevation of albumin levels could 
not be eff ected by MARS, but rather by the simultane-
ous supplement therapy. According to the results, the 
calculated MELD score before and after MARS treat-
ments showed a minimal, but signiﬁ cant decrease (32.1 
± 4.5 to 28.4 ± 4.2, p = 0.0287). It is obvious that the 
separate MARS treatments’ detoxicating eff ect together 
with supplemental therapy slows down the course of liv-
er failure. Comparison of Table I and Table III draws to 
attention, that the individual MARS treatments were ef-
fective in diminishing the blood level of toxic substances; 
therefore, a decrease in average calculated MELD score 
was also observed. In spite of this fact, the complete se-
quence of MARS therapy could not reverse the progres-
sion of the liver failure. Thus, the reOLT was performed 
besides an increased MELD score compared to the one 
before MARS therapy. For case 2 and case 3, it is to be 
mentioned, that more time had passed in the state of 
a liver failure, proving that the natural process of liver 
insuffi  ciency irreversibly deteriorates along with the ap-
plied MARS therapy.
Discussion
Several publications refer on the effi  cacy and eff ect of 
extracorporeal liver supplementary device therapy. Indi-
cation for application of such devices is ALF, AoCLF, 
HE, HRS, and less likely drug intoxication. Also, a pos-
sible application is a temporary treatment after extended 
hepatic resections until the regeneration of the liver. It 
is already proven that water-soluble and albumin-con-
jugated toxin elimination in liver failure patients are all 
performed by SPAD, MARS, and Prometheus as well [9, 
10]. Although slight diff erences are also shown, accord-
ing to published studies, Prometheus system seems to be 
more eff ective in eliminating albumin bound toxin levels 
(ammonia, direct bilirubin, and urea) than MARS [2, 9, 
11]. In the three cases of our study, we found that both 
direct and indirect bilirubin, lactate, and both creatinine 
and urea levels signiﬁ cantly decreased; however, the se-
rum ammonia level slightly increased. 
Hepatic encephalopathy evolves in the basis of high 
toxin levels in the serum that leads to cerebral edema. 
Wang et al. presented a summary of 252 cases of acute 
liver failure patients treated with MARS and proved the 
decrease of hepatic encephalopathy [12]. Kantola et al. 
[17] had come to the same conclusion regarding the ef-
fect of MARS on HE. On the other hand, it turned out 
that HE is the second, the most important prognostic 
factor in the survival of LF, besides the etiology itself. 
They also declared that MARS treatment is ineff ective 
in case of AoCLF, unless a coming OLT is in sight [13]. 
Publications are controversial about the eff ect of MARS 
on HRS by eliminating vasodilatating substances. While 
Wang et al. [12] found MARS to have a beneﬁ cial eff ect 
on HRS, Wong et al. [14] observed six patients with 
refractory ascites and cirrhosis, and although he found 
decrease in the serum nitrogen-oxide levels, no signiﬁ -
cant diff erence was observed in the neurohormone and 
cytokine levels; thus, no eff ect on HRS could be proved 
clearly [14]. Several studies refer to cytokine (IL-1, IL-6 
IL-10, and TNF-α) levels decreased by MARS [14, 15]. 
In terms of survival, Hessel et al. reported an analysis 
of 149 patients with AoCLF of which 67 had received 
MARS therapy. A gain of 0.66 life years was calculated in 
favor to the MARS-treated patients compared to those 
who were only treated with standard medication. This 
report also showed the acceptable cost eff ectiveness of 
MARS [16]. Kantola et al. summarized a 10-year experi-
ence and referred to a 6-month improvement of patient 
survival, both with or without OLT [17]. Several analy-
ses refer to the suitability of MARS for patients suff er-
ing from AoCLF for any reasons and ALF due to graft 
failure of a transplanted liver or for other reasons. As we 
found in our cases, these publications also show that, in 
terms of survival, the use of MARS alone is not eff ective 
enough due to MOF, but the application of MARS fol-
lowed by a OLT/reOLT procedure is highly successful 
[13, 17, 18].
More and more centers report on successful treat-
ments with MARS as a bridging therapy prior to OLT. 
Liu et al. reported two cases of liver transplant patients 
who suff ered PNF after transplantation possible due 
to extended cold ischemic time. They used MARS as a 
bridging therapy to reOLT [19]. Ding et al. reported 8 
cases with AoCLF who were treated with MARS, and 
then successful OLT was performed [20]. Novelli et al. 
reported a series of 18 patients after OLT, suff ering from 
PNF and getting continuous MARS treatment. In this 
study, 11 patients survived, 6 with retransplantation and 
5 without it. Of the 7 patients who died, 4 had passed 
after and 3 before reOLT [21]. We presented two cases 
of post-transplant patients who underwent OLT and 
acute liver failure by PNF, possibly evolved due to the 
combination of prolonged warm ischemic time, usage of 
an extended criteria donor organ, and surgical complica-
tions. Both patients were treated with MARS, multiple 
MARS therapy
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times for ALF as a bridging therapy to successful reOLT, 
which was performed within a few days. Both of them 
has fully recovered and still alive to date.
The third introduced case was a young female who 
were 7 years after the primary liver transplantation. The 
possible recurring chronic liver disease (PSC) turned 
into a fulminated clinical setting because of the repeated 
cholangitis and this deterioration led to an AoCLF. A se-
ries of MARS treatment was performed to gain time be-
fore liver retransplantation could be performed. Twenty-
ﬁ ve months of disease free survival was recorded after 
reOLT when the recurring PSC, and cholangitis ﬁ nally 
developed fatal MOF. All three patients were eff ectively 
treated with MARS and obviously showed us that, to-
gether with conventional renal replacement therapy and 
good conventional intensive care, MARS is a suitable 
bridging therapy before liver retransplantation for graft 
failure ALF or AoCLF patients.
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